おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
G1 Therapeutics
company
About
G1 Therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology.
- 101 - 250
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- $100M
- Industries
- Biotechnology,Developer Platform,Medical,Therapeutics
- Founded date
- Jan 1, 2008
- Number Of Employee
- 101 - 250
- Operating Status
- Active
G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It is also advancing rintodestrant, a potential oral selective estrogen receptor degrader, or serd, for the treatment of er+ breast cancer. It is committed to improving the lives of those impacted by cancer. It is also executing a tumor-agnostic development program, with late-stage clinical trials ongoing in multiple tumor types.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$100M
G1 Therapeutics has raised a total of
$100M
in funding over 2 rounds. Their latest funding was raised on
Jun 1, 2020 from a Post-IPO Debt round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 1, 2020 | Post-IPO Debt | $100M | 1 |
Hercules Capital
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
G1 Therapeutics is funded by 1 investors.
Hercules Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Hercules Capital
|
Yes | Post-IPO Debt |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
